Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.53 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | RARG | P13631 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7322460 | 0.89 | MKNK1 (0.53) | MKNK1MKNK2FYN | |
| SCHEMBL2253452 | 0.87 | NPSR1 (0.56) | MKNK1MKNK2FYNKDM4ENPC1 | |
| SCHEMBL25421528 | 0.85 | MKNK1 (0.72) | MKNK1MKNK2 | |
| SCHEMBL2250931 | 0.82 | FYN (0.60) | MKNK1MKNK2FYNLMNANPSR1 | |
| SCHEMBL2257557 | 0.82 | DCTPP1 (0.52) | MKNK1MKNK2FYNKDM4ENPC1 | |
| SCHEMBL25260642 | 0.82 | ITGA2B (0.46) | MKNK1MKNK2RARARARBRARG | |
| SCHEMBL7326113 | 0.81 | RARB (0.55) | MKNK1MKNK2FYNRARB | |
| SCHEMBL6132721 | 0.79 | RARB (0.59) | MKNK1MKNK2RARB | |
| SCHEMBL6132847 | 0.79 | MKNK1 (0.51) | MKNK1MKNK2RARB | |
| SCHEMBL11374080 | 0.78 | NPC1 (0.44) | MKNK1MKNK2FYNKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | MKNK1 3058/4885MKNK2 3712/4885FYN 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.